A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
Completed · Phase 1 · NCT06493409
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $1,500
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 32
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Repotrectinib (drug), Voriconazole (drug), Quinidine (drug)
- Dates
- Started 2024-08-26; completion 2024-12-07
- Results posted
- Not yet
The purpose of this study is to evaluate the effects of coadministration of voriconazole or quinidine on the pharmacokinetics (PK) of repotrectinib in healthy male and female (individual not of childbearing potential \[INOCBP\]) participants.
From ClinicalTrials.gov, last updated 2025-08-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $1,500 in research payments for this study in 2025 (1 payments).
Products named: Augtyro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research $1,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.